Composition of ropivacaine or its pharmaceutically acceptable salt and use thereof

By controlling the particle size of ropivacaine suspension and solid composition and adding stabilizers to form regular crystals, the problems of complex production and poor sustained-release effect of long-acting ropivacaine formulations are solved, achieving long-acting analgesia and good stability.

CN117959252BActive Publication Date: 2024-11-12NANJING DELOVA BIOTECH CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202310933637.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-27
Publication Date
2024-11-12
Estimated Expiration
2043-07-27

AI Technical Summary

Technical Problem

Existing long-acting ropivacaine formulations suffer from problems such as complex manufacturing processes, difficulty in quality control, insufficient safety and stability, high costs, and poor sustained-release effects, making it difficult to meet the long-acting analgesia needs for postoperative pain.

Method used

To develop a suspension and solid composition of ropivacaine or its pharmaceutically acceptable salts, which, by controlling particle size and adding stabilizers, dispersants, and other components, forms a regular crystal morphology, achieves slow release, simplifies the production process, and improves quality control.

Benefits of technology

It achieves long-lasting analgesia, has good stability, controllable quality, is easy to mass-produce, has few side effects, and is suitable for long-lasting analgesia of postoperative pain, with a continuous release time of up to several days.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004362719050000011
    Figure BDA0004362719050000011
  • Figure BDA0004362719050000131
    Figure BDA0004362719050000131
  • Figure BDA0004362719050000132
    Figure BDA0004362719050000132
Patent Text Reader

Abstract

The present invention belongs to the field of pharmaceutical preparations, and provides a composition of ropivacaine or a pharmaceutically acceptable salt thereof and its use. The suspension and solid composition of the present invention can be sterile by sterilizing filtration, and the obtained composition has good stability, controllable product quality, easy administration, low irritation, and good drug safety and tolerance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and specifically relates to a composition of ropivacaine or a pharmaceutically acceptable salt thereof, in particular to a suspension or solid composition of long-acting ropivacaine or a pharmaceutically acceptable salt thereof. Background Art

[0002] Postoperative pain is acute moderate to severe pain that occurs immediately after surgery and usually lasts no more than 7 days. Reports show that about 75% of surgical patients experience postoperative pain, and more than 50% of patients cannot get adequate pain relief. Inadequate postoperative pain control may lead to adverse physiological reactions in patients after surgery and increase the risk of chronic pain after surgery.

[0003] In order to deal with the above risks of postoperative pain, patients are usually required to take analgesics in clinical practice. Such drugs mainly include opioid analgesics represented by morphine, non-steroidal anti-inflammatory drugs represented by aspirin, and local anesthetics represented by bupivacaine. At present, opioid analgesics occupy most of the analgesic market share. Although it has a strong analgesic effect, it is easy to cause adverse reactions in various systems throughout the body. According to statistics from the US Centers for Disease Control and Prevention, as of 2017, about 15 out of every 100,000 deaths in the United States were related to overdose of opioids.

[0004] The consensus of clinical postoperative management in China is to reduce the use of opioids and use multimodal analgesia to treat surgical pain, but there are still shortcomings. For example, the use of local anesthetics to treat postoperative pain can avoid the adverse reactions of opioids, but the current local anesthetics usually have a short duration of action, and the efficacy can only last for a few hours after a single dose, which cannot meet the needs of the treatment cycle of postoperative pain. Therefore, the clinical demand for long-acting non-opioid drugs for the treatment of postoperative pain has not been met. Prolonging the effective analgesic time of local anesthetics and reducing the use of opioids are current research hotspots.

[0005] At present, the long-acting local anesthetics available in foreign countries all use bupivacaine or its salt as the active ingredient and adopt liposome Collagen implants Polyorthoester polymer Sucrose Acetate Isobutyrate As a sustained-release platform, the above technologies have complex production processes, insufficient analgesic time or excipient safety issues. In addition, bupivacaine has very limited dosage due to its central nervous system and cardiovascular toxicity.

[0006] Compared with bupivacaine, ropivacaine shown in the following formula has the advantages of lower toxicity, higher safety, and higher tolerance dose, and has been developed as a long-acting local anesthetic that is expected to replace bupivacaine.

[0007]

[0008] Ropivacaine

[0009] Currently available long-acting ropivacaine preparations mainly include preparations based on oil-based sustained-release systems, lipid-based sustained-release systems, polymer-based sustained-release systems, and suspension-based sustained-release systems. However, the above systems still have the following defects:

[0010] The drug release process of the oil-based sustained-release system preparation is that the dissolved drug molecules are distributed from the oil-based preparation into the aqueous interstitial fluid and then absorbed into the blood. Therefore, the sustained-release effect of the drug is closely related to the time when the drug is released from the preparation. It is difficult to achieve a sustained release of 3 days or longer using the oil system.

[0011] The preparation process of lipid-based sustained-release systems and polymer-based microsphere sustained-release systems is often complicated and difficult to achieve commercial production. There are also quality control issues. For sustained-release preparations containing polymers, there is a problem of local accumulation caused by the long degradation cycle of the polymer in the body. In addition, the degradation products of PLGA-based sustained-release systems include glycolic acid and lactic acid, and the acidic degradation products may cause inflammatory side effects at the site of administration, which is not conducive to treatment.

[0012] Suspension systems are currently prepared by a "top-down" method, that is, large-sized drug particles are crushed to the desired particle size by mechanical means. Currently, the more commonly used top-down methods include wet and airflow grinding, high-speed shearing and high-pressure homogenization. However, such methods require the use of sterile raw materials and sterile environments, and the risk of sterility assurance is high, resulting in a more difficult production process and higher costs.

[0013] Therefore, it is urgent to develop a long-acting ropivacaine preparation suitable for injection, which has good stability, safety and / or tolerability. It is worth expecting that the long-acting ropivacaine preparation also has advantages such as easy large-scale production and controllable quality. Summary of the invention

[0014] To improve the above defects, the present invention provides a suspension of ropivacaine or a pharmaceutically acceptable salt thereof, a solid composition, and a preparation method and use thereof as described below. The present invention also provides a preparation method of a solid composition suitable for ropivacaine and other active pharmaceutical ingredients and a solid composition obtained by the preparation method.

[0015] The present invention provides a suspension of ropivacaine or a pharmaceutically acceptable salt thereof, wherein the suspension comprises:

[0016] a) ropivacaine or a pharmaceutically acceptable salt thereof;

[0017] Wherein, the ropivacaine or a pharmaceutically acceptable salt thereof in the suspension exists in a particle form, for example, in a crystal form, preferably in a regular crystal form, such as a rod-shaped crystal form or a block crystal form.

[0018] According to an embodiment of the present invention, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension is less than or equal to 200 μm, or less than or equal to 150 μm, or less than or equal to 120 μm, or less than or equal to 100 μm. Preferably, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension is 10 to 90 μm, for example 10 to 80 μm, preferably 10 to 70 μm, more preferably 10 to 60 μm. As an example, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension may be 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm or 60 μm.

[0019] According to an embodiment of the present invention, the pharmaceutically acceptable salt of ropivacaine is an acid salt of ropivacaine, i.e., an addition salt of ropivacaine and a pharmaceutically acceptable acid. For example, the acid salt of ropivacaine includes, but is not limited to, one or more of the following salts selected from ropivacaine: acetate, benzoate, benzenesulfonate, hydrobromide, camphorsulfonate, hydrochloride, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hydroiodide, isethionate, lactate, lactobionate, dodecyl sulfate, malate, maleate, methanesulfonate, naphthoate, naphthylsulfonate, nitrate, stearate, palmitate, myristate, laurate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, trifluoroacetate.

[0020] It should be understood that in the context of this specification, the molar ratio of ropivacaine to the anion of the pharmaceutically acceptable acid is a ratio that makes the pharmaceutically acceptable salt of ropivacaine electrically neutral. For example, when the pharmaceutically acceptable acid is a monobasic acid, the molar ratio of the pharmaceutically acceptable acid to ropivacaine is 1:1; when the pharmaceutically acceptable acid is a dibasic acid, the molar ratio of the pharmaceutically acceptable acid to ropivacaine is 1:2.

[0021] According to an embodiment of the present invention, the suspension optionally further comprises:

[0022] b) a pharmaceutically acceptable stabilizer.

[0023] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from high carbon alcohols (such as C 18 ~C 30 High carbon alcohol), C 18 ~C 30 One or more acids or their salts.

[0024] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salts, deoxycholic acid or its salts, taurodeoxycholic acid or its salts, ursodeoxycholic acid or its salts, chenodeoxycholic acid or its salts, and glycocholic acid or its salts.

[0025] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, taurodeoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, sodium taurodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, and sodium glycocholate.

[0026] According to an embodiment of the present invention, the molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the stabilizer is 0.5:1 to 30:1, preferably 1:1 to 15:1, preferably 1:1 to 10:1, more preferably 1:1 to 7:1, more preferably 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1.

[0027] According to an embodiment of the present invention, the suspension optionally further comprises:

[0028] c) a pharmaceutically acceptable dispersant.

[0029] According to an embodiment of the present invention, the pharmaceutically acceptable dispersant is selected from one or more of polysorbate (Tween), poloxamer, polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, sucrose fatty acid esters, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate (HS-15), and phospholipids.

[0030] According to an embodiment of the present invention, the polysorbate is selected from one or more of polysorbate 80 (Tween 80) and polysorbate 20 (Tween 20).

[0031] According to an embodiment of the present invention, the phospholipid is selected from one or more of DMPC (dimyristoylphosphatidylcholine), DPPC (dipalmitoylphosphatidylcholine), DLPC (dilauroylphosphatidylcholine), SPC soybean phosphatidylcholine (soy lecithin), EPC (egg yolk phospholipids), DEPC (dierucoyl phosphatidylcholine), DOPC (dioleoyl phosphatidylcholine), POPC (palmitoyl oleoyl phosphatidylcholine).

[0032] According to an embodiment of the present invention, the molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable dispersant is 50:1 to 1:1, preferably 40:1 to 2:1, more preferably 30:1 to 2:1, more preferably 20:1 to 2:1, more preferably 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1.

[0033] According to an embodiment of the present invention, the suspension optionally further comprises:

[0034] d) a clinically acceptable diluent.

[0035] According to an embodiment of the present invention, clinically acceptable diluents include but are not limited to one or more of water for injection, sodium chloride injection, glucose injection, lactated Ringer's solution, sucrose aqueous solution, xylitol aqueous solution, and pH buffer solution.

[0036] According to an embodiment of the present invention, the sodium chloride injection includes but is not limited to 0.9% sodium chloride injection.

[0037] According to an embodiment of the present invention, the glucose injection includes but is not limited to 5% glucose injection.

[0038] According to an embodiment of the present invention, the pH buffer is a buffer with a pH of 5.0 to 7.4, including but not limited to one or more of phosphate buffer, glycine buffer, histidine buffer, citrate buffer, and acetate buffer.

[0039] According to an embodiment of the present invention, the suspension is a suspension injection.

[0040] According to an embodiment of the present invention, in the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is about 0.1 mg / mL to about 300 mg / mL, preferably about 1 mg / mL to about 50 mg / mL, and more preferably about 2.5 mg / mL to about 40 mg / mL. As an example, in the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is about 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 1.5 mg / mL, 2 mg / mL, 2.5 mg / mL, 3 mg / mL, 3.5 mg / mL, 4 mg / mL, 4.5 mg / mL, 5 mg / mL, 5.5 mg / mL, 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.5 mg / mL, 8 mg / mL, 8.5 mg / mL. / mL, 9 mg / mL, 9.5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, 55 mg / mL, 60 mg / mL, 65 mg / mL, 70 mg / mL, 75 mg / mL, 80 mg / mL, 85 mg / mL, 90 mg / mL, 95 mg / mL, or 100 mg / mL.

[0041] According to an embodiment of the present invention, the suspension optionally further comprises:

[0042] e) pharmaceutically acceptable inorganic salts.

[0043] According to an embodiment of the present invention, the pharmaceutically acceptable inorganic salt has a water solubility of greater than 10 g / 100 mL at 20°C.

[0044] According to an embodiment of the present invention, the pharmaceutically acceptable inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride; preferably one or more of sodium chloride, potassium sulfate, magnesium chloride, magnesium sulfate, potassium chloride, and calcium chloride.

[0045] According to an embodiment of the present invention, the molar ratio of the ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable inorganic salt is ≥1:0.02, preferably 1:0.02 to 1:2.0, examples of which are 1:0.02, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.7, 1:1.8, 1:1.9 or 1:2.0.

[0046] According to an embodiment of the present invention, the suspension optionally further comprises:

[0047] f) a pharmaceutically acceptable pH adjusting agent.

[0048] According to an embodiment of the present invention, the pH adjuster is selected from alkaline pH adjusters and acidic pH adjusters.

[0049] According to an embodiment of the present invention, the alkaline pH regulator is selected from one or more of meglumine, tromethamine, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, magnesium hydroxide, calcium hydroxide, sodium phosphate, disodium hydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, sodium citrate, sodium acetate, potassium acetate, ammonium acetate, triethylamine, ethanolamine, and diethanolamine; preferably one or more of sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium hydroxide.

[0050] According to an embodiment of the present invention, the acidic pH regulator is selected from one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, ascorbic acid, lactic acid, acetic acid, methanesulfonic acid, oxalic acid, sulfuric acid, glycine, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; preferably one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, lactic acid, and acetic acid.

[0051] According to an embodiment of the present invention, the pH value of the suspension is 6.0-9.0, preferably 6.0-8.5, preferably 6.0-8.0, more preferably 6.0-7.5, more preferably 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4.

[0052] According to an embodiment of the present invention, the ropivacaine in the suspension can also be prepared in situ, for example, by reacting a pharmaceutically acceptable salt of ropivacaine with a base, preferably by reacting a pharmaceutically acceptable salt of ropivacaine with an alkaline pH regulator. Wherein, the pharmaceutically acceptable salt of ropivacaine has the definition described above.

[0053] According to an embodiment of the present invention, when ropivacaine is prepared in situ as described above, the molar ratio of the pharmaceutically acceptable salt of ropivacaine to the alkaline pH regulator can be 1:0.5 to 1:2.0, preferably 1:0.8 to 1:1.5, preferably 1:1.0 to 1:1.2. As an example, the molar ratio of the pharmaceutically acceptable salt of ropivacaine to the alkaline pH regulator is 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 or 1:2.0.

[0054] According to an embodiment of the present invention, the suspension optionally further comprises:

[0055] g) a pharmaceutically acceptable osmotic pressure regulating agent.

[0056] According to an embodiment of the present invention, the osmotic pressure regulator is selected from one or more of sodium chloride, mannitol, lactose, glucose, sorbitol, sorbitol and glycerol, preferably one or more of sodium chloride, glucose, sorbitol and mannitol.

[0057] According to an embodiment of the present invention, the osmotic pressure of the suspension injection is equivalent to the physiological osmotic pressure.

[0058] According to an embodiment of the present invention, the suspension optionally further comprises:

[0059] h) a pharmaceutically acceptable lyoprotectant.

[0060] According to an embodiment of the present invention, the pharmaceutically acceptable lyoprotectant is selected from one or more of mannitol, lactose, trehalose, sucrose, maltose, dextrin, stachyose, gelatin, pectin, sugar alcohol, sorbitol, proline, histidine, lysine, arginine, polyethylene glycol or polyvinyl pyrrolidine, preferably one or more of mannitol, lactose, trehalose, sucrose and polyvinyl pyrrolidine.

[0061] According to an embodiment of the present invention, the suspension optionally does not contain a pharmaceutically acceptable suspending agent. The suspending agent is preferably a water-soluble polymer compound, including but not limited to one or more of carboxymethyl cellulose or its sodium salt, hydroxypropyl cellulose or its sodium salt, hydroxypropyl methyl cellulose or its sodium salt, methyl cellulose or its sodium salt, hydroxyethyl cellulose or its sodium salt, sodium hyaluronate and polyvinyl pyrrolidone.

[0062] The present invention also provides a single-dose form or a multiple-dose form of the suspension, wherein each dosage unit of the single-dose form or the multiple-dose form contains 5 mg to 1200 mg of ropivacaine or a pharmaceutically acceptable salt thereof equivalent to ropivacaine free base, preferably 20 mg to 1200 mg, more preferably 40 mg to 1200 mg. Preferably, each dosage unit of the single-dose form or the multiple-dose form is contained in a separate container.

[0063] The present invention also provides a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof, characterized in that the solid composition comprises:

[0064] i) ropivacaine or a pharmaceutically acceptable salt thereof;

[0065] Wherein, the ropivacaine or a pharmaceutically acceptable salt thereof in the solid composition exists in a particle form, for example, in a crystal form, preferably in a regular crystal form, such as a rod-shaped or block-shaped crystal form.

[0066] According to an embodiment of the present invention, in the solid composition, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof is less than or equal to 200 μm, or less than or equal to 150 μm, or less than or equal to 120 μm, or less than or equal to 100 μm. Preferably, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension is 10 to 90 μm, for example, 10 to 80 μm, preferably 10 to 70 μm, and more preferably 10 to 60 μm. As an example, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension may be 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm or 60 μm.

[0067] According to an embodiment of the present invention, the pharmaceutically acceptable salt of ropivacaine is an acid salt of ropivacaine, i.e., an addition salt of ropivacaine and a pharmaceutically acceptable acid. For example, the acid salt of ropivacaine includes, but is not limited to, one or more of the following salts selected from ropivacaine: acetate, benzoate, benzenesulfonate, hydrobromide, camphorsulfonate, hydrochloride, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hydroiodide, isethionate, lactate, lactobionate, dodecyl sulfate, malate, maleate, methanesulfonate, naphthoate, naphthylsulfonate, nitrate, stearate, palmitate, myristate, laurate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, trifluoroacetate.

[0068] According to an embodiment of the present invention, the solid composition may further comprise:

[0069] ii) a pharmaceutically acceptable stabilizer.

[0070] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from high carbonic acid (such as C 18 ~C 30 High carbon alcohol), C 18 ~C 30 One or more acids or their salts.

[0071] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salts, deoxycholic acid or its salts, taurodeoxycholic acid or its salts, ursodeoxycholic acid or its salts, chenodeoxycholic acid or its salts, and glycocholic acid or its salts.

[0072] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecanol, cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.

[0073] According to an embodiment of the present invention, the molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the stabilizer is 0.5:1 to 30:1, preferably 1:1 to 15:1, preferably 1:1 to 10:1, more preferably 1:1 to 7:1, more preferably 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1.

[0074] According to an embodiment of the present invention, the solid composition may further comprise:

[0075] iii) a pharmaceutically acceptable dispersant.

[0076] According to an embodiment of the present invention, the pharmaceutically acceptable dispersant is selected from one or more of polysorbate (Tween), poloxamer, polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, sucrose fatty acid esters, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate (HS-15), and phospholipids.

[0077] According to an embodiment of the present invention, the polysorbate is selected from one or more of polysorbate 80 (Tween 80) and polysorbate 20 (Tween 20).

[0078] According to an embodiment of the present invention, the phospholipid is selected from one or more of DMPC (dimyristoylphosphatidylcholine), DPPC (dipalmitoylphosphatidylcholine), DLPC (dilauroylphosphatidylcholine), SPC soybean phosphatidylcholine (soy lecithin), EPC (egg yolk phospholipids), DEPC (dierucoyl phosphatidylcholine), DOPC (dioleoyl phosphatidylcholine), POPC (palmitoyl oleoyl phosphatidylcholine).

[0079] According to an embodiment of the present invention, the molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable dispersant is 50:1 to 1:1, preferably 40:1 to 2:1, more preferably 30:1 to 2:1, more preferably 20:1 to 2:1, more preferably 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1.

[0080] According to an embodiment of the present invention, the solid composition may further comprise:

[0081] iv) pharmaceutically acceptable inorganic salts.

[0082] According to an embodiment of the present invention, the solubility of the pharmaceutically acceptable inorganic salt in water at 20° C. is greater than 10 g / 100 mL.

[0083] According to an embodiment of the present invention, the solid composition optionally comprises: an inorganic salt selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride; preferably one or more of sodium chloride, potassium sulfate, magnesium chloride, magnesium sulfate, potassium chloride, and calcium chloride.

[0084] According to an embodiment of the present invention, the molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to a pharmaceutically acceptable inorganic salt is ≥1:0.02, preferably 1:0.02 to 1:2.0, and more preferably 1:0.02, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.7, 1:1.8, 1:1.9, 1:2.0.

[0085] According to an embodiment of the present invention, the solid composition may further comprise:

[0086] v) a pharmaceutically acceptable pH adjusting agent.

[0087] According to an embodiment of the present invention, the pH adjuster is selected from alkaline pH adjusters and acidic pH adjusters.

[0088] According to an embodiment of the present invention, the alkaline pH regulator is selected from one or more of meglumine, tromethamine, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, magnesium hydroxide, calcium hydroxide, sodium phosphate, disodium hydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, sodium citrate, sodium acetate, potassium acetate, ammonium acetate, triethylamine, ethanolamine, and diethanolamine; preferably one or more of sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium hydroxide.

[0089] According to an embodiment of the present invention, the acidic pH regulator is selected from one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, ascorbic acid, lactic acid, acetic acid, methanesulfonic acid, oxalic acid, sulfuric acid, glycine, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; preferably one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, lactic acid, and acetic acid.

[0090] According to an embodiment of the present invention, the solid composition is reconstituted to form a suspension.

[0091] According to an embodiment of the present invention, the pH value of the suspension is 6.0-9.0, preferably 6.0-8.5, preferably 6.0-8.0, more preferably 6.0-7.5, more preferably 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4.

[0092] According to an embodiment of the present invention, the solid composition may further comprise:

[0093] vi) a pharmaceutically acceptable osmotic pressure regulating agent.

[0094] According to an embodiment of the present invention, the pharmaceutically acceptable osmotic pressure regulator is selected from one or more of sodium chloride, mannitol, lactose, glucose, sorbitol, sorbitol and glycerol, preferably one or more of sodium chloride, glucose, sorbitol and mannitol.

[0095] According to an embodiment of the present invention, the solid composition may further comprise:

[0096] vii) a pharmaceutically acceptable lyoprotectant.

[0097] According to an embodiment of the present invention, the pharmaceutically acceptable lyoprotectant is selected from one or more of mannitol, lactose, trehalose, sucrose, maltose, dextrin, stachyose, gelatin, pectin, sugar alcohol, sorbitol, proline, histidine, lysine, arginine, polyethylene glycol or polyvinyl pyrrolidine, preferably one or more of mannitol, lactose, trehalose, sucrose and polyvinyl pyrrolidine.

[0098] According to an embodiment of the present invention, the solid composition optionally does not contain a pharmaceutically acceptable suspending agent, and the suspending agent is preferably a water-soluble polymer compound, including but not limited to one or more of carboxymethyl cellulose or its sodium salt, hydroxypropyl cellulose or its sodium salt, hydroxypropyl methyl cellulose or its sodium salt, methyl cellulose or its sodium salt, hydroxyethyl cellulose or its sodium salt, sodium hyaluronate and polyvinyl pyrrolidone.

[0099] The present invention also provides a method for preparing a solid pharmaceutical composition, the method comprising: drying a solution containing active pharmaceutical ingredients to obtain the solid composition.

[0100] According to an embodiment of the present invention, in the solid pharmaceutical composition obtained after drying, the pharmaceutically active ingredient exists in the form of particles, such as in the form of crystals, preferably in the form of regular crystals, such as rod-shaped crystals or block-shaped crystals.

[0101] According to an embodiment of the present invention, the preparation method comprises: sterilizing, filtering and drying a solution containing a pharmaceutically active ingredient to obtain the solid pharmaceutical composition.

[0102] According to an embodiment of the present invention, in the solid pharmaceutical composition obtained after drying, the D90 particle size of the active pharmaceutical ingredient is less than or equal to 200 μm, or less than or equal to 150 μm, or less than or equal to 120 μm, or less than or equal to 100 μm. Preferably, the D90 particle size of the active pharmaceutical ingredient is 10 to 90 μm, for example, 10 to 80 μm, preferably 10 to 70 μm, and more preferably 10 to 60 μm. As an example, the D90 particle size of the active pharmaceutical ingredient can be 10 μm, 15 μm, 20 μm, 25 μm, 30 μm, 35 μm, 40 μm, 45 μm, 50 μm, 55 μm or 60 μm.

[0103] According to an embodiment of the present invention, the drying method includes evaporative drying, freeze drying, spray drying, preferably freeze drying.

[0104] According to an embodiment of the present invention, the freeze-drying includes a pre-freezing process and a drying process.

[0105] According to an embodiment of the present invention, freeze drying can be performed in containers such as vials.

[0106] According to an embodiment of the present invention, the pharmaceutically active ingredient may be dissolved in a solvent to form the solution containing the pharmaceutically active ingredient.

[0107] According to an embodiment of the present invention, the solvent can be selected from an inorganic solvent, an organic solvent or a mixture thereof suitable for dissolving the active pharmaceutical ingredient. For example, the solvent is water, an organic solvent or a co-solvent system comprising water and an organic solvent, preferably one or more of water, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, the tert-butanol, acetone, acetonitrile, methylene chloride, and dimethyl sulfoxide, more preferably water, ethanol, isopropanol, the tert-butanol, or a co-solvent system comprising water and one or more selected from the following organic solvents: methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, the tert-butanol, acetone, acetonitrile, methylene chloride, and dimethyl sulfoxide. For example, the co-solvent system is selected from a co-solvent system comprising water and one selected from the following organic solvents: ethanol, isopropanol, the tert-butanol.

[0108] According to an embodiment of the present invention, in the co-solvent system of water and an organic solvent, the volume percentage of the organic solvent is 1% to 99%, for example 10% to 90%, preferably 50% to 90%, and examples thereof may be 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%.

[0109] For example, the co-solvent system of water and organic solvent is selected from the co-solvent system of water and tert-butyl alcohol. In the co-solvent system, the volume percentage of tert-butyl alcohol can be 50-95%, preferably 60-90%, more preferably 65-85%, and its example is 65%, 70%, 75%, 80% or 85%.

[0110] According to an embodiment of the present invention, when the solubility of the pharmaceutically active ingredient in water is lower than that in an organic solvent, the solvent is selected from a co-solvent system comprising water and the organic solvent.

[0111] According to an embodiment of the present invention, the mass volume ratio of the pharmaceutically active ingredient to the solvent is ≥1 mg / mL, preferably ≥5 mg / mL, for example ≥10 mg / mL.

[0112] According to an embodiment of the present invention, the solution containing the active pharmaceutical ingredient may further contain:

[0113] 1) Pharmaceutically acceptable stabilizer.

[0114] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from high carbonic acid (such as C 18 ~C 30 High carbon alcohol), C 18 ~C 30 One or more acids or their salts.

[0115] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salts, deoxycholic acid or its salts, taurodeoxycholic acid or its salts, ursodeoxycholic acid or its salts, chenodeoxycholic acid or its salts, and glycocholic acid or its salts.

[0116] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.

[0117] According to an embodiment of the present invention, the molar ratio of the pharmaceutical active ingredient to the stabilizer is 0.5:1 to 30:1, preferably 1:1 to 15:1, preferably 1:1 to 10:1, more preferably 1:1 to 7:1, more preferably 1:1, 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1, 6.5:1, 7:1.

[0118] According to an embodiment of the present invention, the solution containing the active pharmaceutical ingredient may further contain:

[0119] 2) Pharmaceutically acceptable dispersants.

[0120] According to an embodiment of the present invention, the pharmaceutically acceptable dispersant is selected from one or more of polysorbate (Tween), poloxamer, polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, sucrose fatty acid esters, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate (HS-15), and phospholipids.

[0121] According to an embodiment of the present invention, the polysorbate is selected from one or more of polysorbate 80 (Tween 80) and polysorbate 20 (Tween 20).

[0122] According to an embodiment of the present invention, the phospholipid is selected from DMPC (dimyristoyl phosphatidylcholine), DPPC (dipalmitoyl phosphatidylcholine), DLPC (dilauroyl phosphatidylcholine), SPC soybean phosphatidylcholine (soy lecithin), EPC (egg yolk phospholipids), DEPC (dierucoyl phosphatidylcholine), DOPC (dioleoyl phosphatidylcholine), POPC (palmitoyl oleoyl phosphatidylcholine) One or more.

[0123] According to an embodiment of the present invention, the molar ratio of the pharmaceutically active ingredient to the pharmaceutically acceptable dispersant is 50:1 to 1:1, preferably 40:1 to 2:1, more preferably 30:1 to 2:1, more preferably 20:1 to 2:1, more preferably 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 12:1, 11:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1.

[0124] According to an embodiment of the present invention, the solution containing the active pharmaceutical ingredient may further contain:

[0125] 3) Pharmaceutically acceptable inorganic salts.

[0126] According to an embodiment of the present invention, the solubility of the pharmaceutically acceptable inorganic salt in water at 20° C. is greater than 10 g / 100 mL.

[0127] According to an embodiment of the present invention, the inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride; preferably one or more of sodium chloride, potassium sulfate, magnesium chloride, magnesium sulfate, potassium chloride, and calcium chloride.

[0128] According to an embodiment of the present invention, the molar ratio of the pharmaceutically active ingredient to the pharmaceutically acceptable inorganic salt is ≥1:0.02, preferably 1:0.02-1:2.0, and more preferably 1:0.02, 1:0.05, 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.7, 1:1.8, 1:1.9, 1:2.0.

[0129] According to an embodiment of the present invention, the solution containing active pharmaceutical ingredients may further contain:

[0130] 4) Pharmaceutically acceptable pH adjusters.

[0131] According to an embodiment of the present invention, the pH adjuster is selected from alkaline pH adjusters and acidic pH adjusters.

[0132] According to an embodiment of the present invention, the alkaline pH regulator is selected from one or more of meglumine, tromethamine, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, magnesium hydroxide, calcium hydroxide, sodium phosphate, disodium hydrogen phosphate, potassium phosphate, dipotassium hydrogen phosphate, sodium citrate, sodium acetate, potassium acetate, ammonium acetate, triethylamine, ethanolamine, and diethanolamine; preferably one or more of sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium hydroxide.

[0133] According to an embodiment of the present invention, the acidic pH regulator is selected from one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, ascorbic acid, lactic acid, acetic acid, methanesulfonic acid, oxalic acid, sulfuric acid, glycine, sodium dihydrogen phosphate, and potassium dihydrogen phosphate; preferably one or more of citric acid, tartaric acid, maleic acid, malic acid, fumaric acid, succinic acid, succinic acid, hydrochloric acid, phosphoric acid, lactic acid, and acetic acid.

[0134] According to an embodiment of the present invention, the solution containing the active pharmaceutical ingredient may further contain:

[0135] 5) Pharmaceutically acceptable osmotic pressure regulator.

[0136] According to an embodiment of the present invention, the osmotic pressure regulator is selected from one or more of sodium chloride, mannitol, lactose, glucose, sorbitol, sorbitol and glycerol, preferably one or more of sodium chloride, glucose, sorbitol and mannitol.

[0137] According to an embodiment of the present invention, the osmotic pressure of the suspension injection is equivalent to the physiological osmotic pressure.

[0138] According to an embodiment of the present invention, the solution containing the active pharmaceutical ingredient may further contain:

[0139] 6) Pharmaceutically acceptable lyoprotectants.

[0140] According to an embodiment of the present invention, the pharmaceutically acceptable lyoprotectant is selected from one or more of mannitol, lactose, trehalose, sucrose, maltose, dextrin, stachyose, gelatin, pectin, sugar alcohol, sorbitol, proline, histidine, lysine, arginine, polyethylene glycol or polyvinyl pyrrolidine, preferably one or more of mannitol, lactose, trehalose, sucrose and polyvinyl pyrrolidine.

[0141] According to an embodiment of the present invention, the solid pharmaceutical composition may optionally not contain a pharmaceutically acceptable suspending agent, and the suspending agent is preferably a water-soluble polymer compound, including but not limited to one or more of carboxymethyl cellulose or its sodium salt, hydroxypropyl cellulose or its sodium salt, hydroxypropyl methyl cellulose or its sodium salt, methyl cellulose or its sodium salt, hydroxyethyl cellulose or its sodium salt, sodium hyaluronate and polyvinyl pyrrolidone.

[0142] According to an embodiment of the present invention, the preparation method comprises: dissolving each component in the solution to obtain a solution, and drying to obtain a solid composition.

[0143] According to an embodiment of the present invention, the preparation method comprises: dissolving each component in the solution to obtain a solution, sterilizing and filtering, and drying to obtain a solid composition.

[0144] According to an embodiment of the present invention, the pharmaceutically active ingredient may be selected from ropivacaine, a pharmaceutically acceptable salt of ropivacaine, or other pharmaceutically active ingredients that can be used for a disease or condition.

[0145] According to an embodiment of the present invention, the solid pharmaceutical composition may be selected from a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof, which may include but is not limited to the solid composition of ropivacaine or a pharmaceutically acceptable salt thereof described in the context of this specification.

[0146] According to an embodiment of the present invention, the pharmaceutically acceptable salt of ropivacaine is an acid salt of ropivacaine, i.e., an addition salt of ropivacaine and a pharmaceutically acceptable acid. For example, the acid salt of ropivacaine includes, but is not limited to, one or more of the following salts selected from ropivacaine: acetate, benzoate, benzenesulfonate, hydrobromide, camphorsulfonate, hydrochloride, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hydroiodide, isethionate, lactate, lactobionate, dodecyl sulfate, malate, maleate, methanesulfonate, naphthoate, naphthylsulfonate, nitrate, stearate, palmitate, myristate, laurate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, trifluoroacetate.

[0147] According to an embodiment of the present invention, when the pharmaceutically active ingredient in the solution is a pharmaceutically acceptable salt, such as a pharmaceutically acceptable acid addition salt or a base addition salt, it can react with a pH adjuster in the solution to prepare in situ the corresponding free active ingredient, such as a free alkaline active ingredient or a free acidic active ingredient.

[0148] Alternatively, when the pharmaceutically active ingredient in the solution is a free alkaline active ingredient or a free acidic active ingredient, it can react with a pH adjuster in the solution to prepare a corresponding pharmaceutically acceptable salt in situ.

[0149] For example, when the pharmaceutically active ingredient in the solution is a pharmaceutically acceptable salt of ropivacaine, ropivacaine can be prepared in situ by reacting the pharmaceutically acceptable salt of ropivacaine with an alkaline pH regulator.

[0150] According to an embodiment of the present invention, the pharmaceutically acceptable salt of ropivacaine has the definition as described above.

[0151] According to an embodiment of the present invention, when a free active ingredient or a pharmaceutically acceptable salt is prepared in situ as described above, the molar ratio of the pharmaceutically active ingredient as a reaction raw material to the pH regulator can be determined by a person skilled in the art, for example, 3:1 to 1:3. For example, when the pharmaceutically active ingredient as a reaction raw material is a pharmaceutically acceptable salt of ropivacaine, its molar ratio to the alkaline pH regulator can be 1:0.5 to 1:2.0, preferably 1:0.8 to 1:1.5, preferably 1:1.0 to 1:1.2. As an example, the molar ratio of the pharmaceutically acceptable salt of ropivacaine to the alkaline pH regulator is 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9 or 1:2.0.

[0152] The present invention also provides a solid pharmaceutical composition prepared by the above preparation method, such as a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof.

[0153] The present invention also provides a method for preparing a suspension, which comprises redissolving the solid pharmaceutical composition to obtain the suspension.

[0154] According to an embodiment of the present invention, the preparation method comprises mixing the above solid pharmaceutical composition with a clinically acceptable diluent to obtain a suspension.

[0155] According to an embodiment of the present invention, the clinically acceptable diluent includes but is not limited to one or more of water for injection, sodium chloride injection, glucose injection, lactated Ringer's solution, sucrose solution, xylitol solution, and pH buffer solution.

[0156] According to an embodiment of the present invention, the sodium chloride injection includes but is not limited to 0.9% sodium chloride injection.

[0157] According to an embodiment of the present invention, the glucose injection includes but is not limited to 5% glucose injection.

[0158] According to an embodiment of the present invention, the pH buffer is selected from a buffer of pH 5.0 to 7.4, for example, including but not limited to one or more of phosphate buffer, glycine buffer, histidine buffer, citrate buffer, and acetate buffer.

[0159] According to an embodiment of the present invention, the pH of the suspension is 6.0-9.0, preferably 6.0-8.5, preferably 6.0-8.0, more preferably 6.0-7.5, more preferably 6.2, 6.4, 6.6, 6.8, 7.0, 7.2, 7.4.

[0160] According to an embodiment of the present invention, the concentration of the active pharmaceutical ingredient in the suspension is about 0.1 mg / mL to about 300 mg / mL, preferably about 1 mg / mL to about 50 mg / mL, and more preferably about 2.5 mg / mL to about 40 mg / mL. As an example, in the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is about 0.1 mg / mL, 0.5 mg / mL, 1 mg / mL, 1.5 mg / mL, 2 mg / mL, 2.5 mg / mL, 3 mg / mL, 3.5 mg / mL, 4 mg / mL, 4.5 mg / mL, 5 mg / mL, 5.5 mg / mL, 6 mg / mL, 6.5 mg / mL, 7 mg / mL, 7.5 mg / mL, 8 mg / mL, 8.5 mg / mL. / mL, 9 mg / mL, 9.5 mg / mL, 10 mg / mL, 15 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, 50 mg / mL, 55 mg / mL, 60 mg / mL, 65 mg / mL, 70 mg / mL, 75 mg / mL, 80 mg / mL, 85 mg / mL, 90 mg / mL, 95 mg / mL, or 100 mg / mL.

[0161] According to an embodiment of the present invention, the suspension is a suspension of ropivacaine or a pharmaceutically acceptable salt thereof, which includes but is not limited to the suspension of ropivacaine or a pharmaceutically acceptable salt thereof described above in the context of this specification.

[0162] The present invention also provides a suspension prepared by the above preparation method, such as a suspension of ropivacaine or a pharmaceutically acceptable salt thereof.

[0163] The present invention also provides the use of a pharmaceutically acceptable inorganic salt and / or a pharmaceutically acceptable stabilizer as a stabilizer for particles (eg, crystals) of ropivacaine or a pharmaceutically acceptable salt thereof.

[0164] The present invention also provides the use of a pharmaceutically acceptable inorganic salt and / or a pharmaceutically acceptable stabilizer as a stabilizer for ropivacaine particles or a pharmaceutically acceptable salt thereof (e.g., crystals) in the method for preparing the above-mentioned suspension of ropivacaine or a pharmaceutically acceptable salt thereof, or a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof.

[0165] According to an embodiment of the present invention, the pharmaceutically acceptable inorganic salt and / or pharmaceutically acceptable stabilizer is used to promote the (stable) presence of ropivacaine or its pharmaceutically acceptable salt in a suspension or solid composition in the form of particles (e.g., crystals), preferably in the form of regular crystals, such as rod-shaped or block-shaped crystals.

[0166] According to an embodiment of the present invention, the inorganic salt is selected from pharmaceutically acceptable inorganic salts having a solubility in water greater than 10 g / 100 mL water at 20°C.

[0167] According to an embodiment of the present invention, the inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride; preferably one or more of sodium chloride, potassium sulfate, magnesium chloride, magnesium sulfate, potassium chloride, and calcium chloride.

[0168] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from C 18 ~C 30 High carbon alcohol, C 18 ~C 30 Acid or its salt.

[0169] According to an embodiment of the present invention, the pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.

[0170] The present invention also provides use of the above suspension or solid composition in preparing a drug for producing anesthesia or relieving pain.

[0171] The present invention also provides use of the above suspension or solid composition in preparing a medicine for treating and / or preventing pain.

[0172] The present invention also provides the above suspension or solid composition, which is used for treating and / or preventing pain.

[0173] According to an embodiment of the present invention, the suspension or solid composition is administered around a nerve or to a surgical wound.

[0174] According to an embodiment of the present invention, the pain is chronic postoperative pain or labor pain.

[0175] The present invention also provides a method for producing anesthesia, comprising administering the above suspension or solid composition to an individual.

[0176] The present invention also provides a method for treating, improving and / or preventing pain, comprising administering the above suspension or solid composition to an individual.

[0177] According to an embodiment of the present invention, the administration is parenteral administration and / or topical administration.

[0178] According to an embodiment of the present invention, parenteral administration is selected from intravenous, intramuscular, subcutaneous injection, intra-articular injection, epidural administration, subarachnoid administration, incisional perfusion administration, infiltration and nerve block, preferably intramuscular, subcutaneous injection, intra-articular injection, epidural administration, subarachnoid administration, incisional perfusion administration, infiltration and nerve block.

[0179] As used herein, the term "individual" includes mammals and humans.

[0180] According to an embodiment of the present invention, the above-mentioned suspension, solid composition provides a sustained release of the drug for not less than 12 hours in an individual. Some embodiments provide a sustained release of the drug for not less than 24 hours. Some embodiments provide a sustained release of the drug for not less than 36 hours. Some embodiments provide a sustained release of the drug for not less than 48 hours. Some embodiments provide a sustained release of the drug for not less than 60 hours. Some embodiments provide a sustained release of the drug for not less than 72 hours. Some embodiments provide a sustained release of the drug for not less than 120 hours. Some embodiments provide a sustained release of the drug for not less than 168 hours.

[0181] According to an embodiment of the present invention, the above-mentioned suspension or solid composition can reach the peak drug concentration within about 3 hours after administration to an individual, for example, within about 2 hours, preferably within about 1.5 hours, more preferably within about 1 hour, and most preferably within about 30 minutes.

[0182] Beneficial Effects

[0183] The present invention provides a new solid composition of ropivacaine and a pharmaceutically acceptable salt thereof. The solid composition preparation is a freeze-dried powder injection, which is a suspension after reconstitution. In the solid composition and the suspension, ropivacaine or a pharmaceutically acceptable salt thereof is stably present in the system in the form of particles (such as crystals).

[0184] Adding an acceptable inorganic salt and / or a pharmaceutically acceptable stabilizer to the above-mentioned formulation system can significantly improve the crystal morphology of ropivacaine or a pharmaceutically acceptable salt thereof in the suspension or solid composition, preferably forming regular crystals of ropivacaine or a pharmaceutically acceptable salt thereof, such as rod-shaped or block-shaped crystals; after administration, the drug crystals slowly dissolve, thereby achieving a slow release effect.

[0185] The suspension (such as suspension injection) and solid composition of the present invention have good stability, controllable product quality, easy administration, low irritation, and good drug safety and tolerance.

[0186] The sustained-release preparation system provided by the present invention can achieve good release performance of active pharmaceutical ingredients and reduce the possibility of sudden release. It is particularly suitable for the development of pharmaceutical preparations with anesthetic and analgesic activities, and has more advantages than other existing technologies, such as simple preparation process, sterility level can be ensured by sterilization filtration, and it is easy to achieve scale-up production. The release of analgesic active ingredients is sustained and stable, and patients have good tolerance and few side effects.

[0187] Terms and abbreviations

[0188] Unless otherwise specified, all numbers used in this specification and claims to indicate content, concentration, ratio, weight, percentage, technical effect, etc. should be understood as modified by the term "about" or "approximately" in any case. "About" represents a range of ±10% of the value it modifies.

[0189] Therefore, unless otherwise indicated, the numerical parameters listed in the following specification and the attached claims are approximate values. Unless otherwise indicated, the terms used herein have the commonly understood meanings to those skilled in the art. For those skilled in the art, it can vary according to the desired properties and effects sought to be obtained through the present disclosure, and each numerical parameter should be interpreted according to the number of significant digits and conventional rounding methods or in a manner understood by those skilled in the art.

[0190] Although the numerical ranges and parameters setting forth the broad scope of the present invention are approximate, the numerical values ​​set forth in the specific embodiments are provided as accurately as possible. However, any numerical value will inherently contain certain errors, which are necessarily caused by the standard deviation found in its corresponding test measurements. Each numerical range given in this specification will include each narrower numerical range that falls within the broader numerical range, just as if these narrower numerical ranges were all clearly written herein.

[0191] Unless otherwise specified, the definitions of excipients recorded in the specification and claims of this application, including their definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, definitions of specific excipients in embodiments, etc., can be arbitrarily combined and combined with each other. Such combined and combined excipients shall fall within the scope of the description of this application.

[0192] The "D50" mentioned in the context of this specification refers to the particle size corresponding to when the cumulative particle size distribution percentage of a sample reaches 50%. "D90" refers to the particle size corresponding to when the cumulative particle size distribution percentage of a sample reaches 90%.

[0193] The term "higher alcohol" refers to higher alkanols, also known as higher fatty alcohols, which include saturated monohydric alcohols that are waxy solids with more than twelve carbon atoms.18 ~C 30 When referring to "higher alcohol", it means C 18 ~C 30 Saturated monohydric alcohol, i.e., saturated monohydric alcohol having 18 to 30 carbon atoms. 18 ~C 30 The higher carbon alcohol can be selected from cholesterol and octadecyl alcohol.

[0194] The term "particle" means a solid geometric body within a certain size range and having a specific shape. Preferably, the particle size of the "particle" in the context of this specification is in the micrometer range.

[0195] The term "regular crystal" means a particle having a specific shape. Regular crystals in the context of this specification may be rod-shaped, spherical, block-shaped, and the like.

[0196] The term "irregular crystals" means particles that do not have a specific shape.

[0197] The osmotic pressure of the pharmaceutical composition is equivalent to the physiological osmotic pressure, and the osmotic pressure of the suspension injection is equivalent to the physiological osmotic pressure, and the meaning of equivalent is: 300±50mmol / L.

[0198] The term "freeze drying" includes a pre-freezing process and a drying process. For example, the pre-freezing process includes a cooling step 1, an annealing step, and a cooling step 2. Or for example, the drying process includes a primary drying step and a secondary drying step.

[0199] The abbreviations used in this specification have the following definitions: TW80 is Tween 80; TW20 is Tween 20; HS-15 is polyethylene glycol-15 hydroxystearate; F68 is poloxamer 188; DMPC is dimyristoylphosphatidylcholine; DPPC is dipalmitoylphosphatidylcholine; DLPC is dilauroylphosphatidylcholine; SPC is soybean phosphatidylcholine (soy lecithin); EPC is egg yolk phospholipids; DEPC is dierucoyl phosphatidylcholine; DOPC is dioleoyl phosphatidylcholine; POPC is palmitoyl oleoyl phosphatidylcholine; HSPC is hydrogenated soybean phosphatidylcholine; DSPC is distearoyl phosphatidylcholine; ROP is ropivacaine; CHO is cholesterol; TBA is tert-butyl alcohol; MgCl 2 6H 2 O is magnesium chloride hexahydrate; NaCl is sodium chloride. BRIEF DESCRIPTION OF THE DRAWINGS

[0200] Figure 1 is a microscopic morphology of ropivacaine in Example composition 6006;

[0201] Figure 2 is a microscopic morphology of ropivacaine in Example compositions 6030 to 6035;

[0202] Figure 3 is a microscopic morphology of ropivacaine in Example compositions 6036, 6037, 6039, 6040, 6041, 6042, 6044 and 6045;

[0203] Figure 4 is a microscopic morphology of ropivacaine in Example compositions 6046 and 6049;

[0204] Figure 5 is a microscopic morphology of ropivacaine in Example compositions 6010 and 6064;

[0205] Figure 6 is a microscopic morphology of ropivacaine in Example compositions 6074, 6076 and 6078;

[0206] Figure 7 is a microscopic morphology of ropivacaine in Example compositions 6083 and 6087;

[0207] Figure 8 is a microscopic morphology of ropivacaine in Example compositions 6091, 6097, 6098 and 6104;

[0208] Fig. 9 The microscopic morphology of ropivacaine after reconstitution of Example Composition 6105 with purified water, sodium chloride aqueous solution and magnesium chloride aqueous solution;

[0209] Fig.10 is a microscopic morphology of ropivacaine in Example compositions 6106 and 6107;

[0210] Fig.11 is an electron microscopic morphology of ropivacaine in Example composition 6106;

[0211] Fig.12 is a microscopic morphology of ropivacaine in Example compositions 6106, 6126, 6127 and 6128;

[0212] Fig.13 is a crystal morphology diagram of ropivacaine of Example composition 6129;

[0213] Fig.14 : is the blood drug concentration curve of Example compositions 6106 and 6143 in rats;

[0214] Fig.15 Comparison of the efficacy of Example Composition 6144 and EXPAREL in rats;

[0215] Fig.16 The local safety comparison between Example composition 6154 and Comparative Example 3 is shown. DETAILED DESCRIPTION

[0216] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0217] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0218] Unless otherwise specified, the percentage content of tert-butyl alcohol (TBA) in the tert-butyl alcohol aqueous solution in the following examples is the volume percentage content. When a percentage lower than 100% is described together with TBA (including but not limited to 80% TBA, 75% TBA, etc.), it means a tert-butyl alcohol aqueous solution with the tert-butyl alcohol content of the percentage. When a percentage of 100% is described together with TBA (i.e., 100% TBA), it means tert-butyl alcohol without additional water.

[0219] Source of experimental animals:

[0220] Beagle: Jiangsu Masi Biotechnology Co., Ltd.; male;

[0221] Rats: Zhejiang Weitong Lihua Experimental Animal Technology Co., Ltd., Animal Experiment Center of Nantong University; male.

[0222] Example 1

[0223] Investigation of conventional freeze-dried compositions

[0224] (1) Compositions containing freeze-drying protective agents

[0225] Weigh the prescribed amount of ropivacaine and lyophilization protective agent according to Table 1-1 into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle (cillin vial), and freeze-dry according to Table 1-3. Add 2mL of physiological saline to the lyophilized powder and shake until it is evenly dispersed, and observe the dispersibility of the re-dissolution under a microscope (Olympus, CX41).

[0226] Table 1-1 Compositions containing freeze-drying protective agents

[0227]

[0228] Table 1-2 Redissolution and dispersibility results

[0229] Composition No. Redispersibility 6001 Unable to disperse 6002 Unable to disperse 6003 Unable to disperse

[0230] Table 1-3 Freeze drying method

[0231]

[0232] The results showed that the composition containing only the lyoprotectant could not be dispersed after reconstitution.

[0233] (2) Compositions containing suspending agents

[0234] Weigh the prescribed amount of ropivacaine and suspending agent according to Table 1-4 into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of saline to the lyophilized powder and shake until it is evenly dispersed, and observe the dispersibility of the re-dissolution under a microscope (Olympus, CX41).

[0235] Table 1-4 Compositions containing suspending agents

[0236]

[0237] Table 1-5 Redissolution and dispersibility results

[0238] Composition No. Solution stability before lyophilization Redispersibility 6004 Clear solution Unable to disperse 6005 Clear solution Unable to disperse

[0239] The results showed that the composition containing only the commonly used suspending agent could not be dispersed after reconstitution.

[0240] Example 2

[0241] Research on dispersants

[0242] (1) Compositions containing common dispersants

[0243] Weigh the prescribed amount of ropivacaine and dispersant according to Table 2-1 into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of saline to the lyophilized powder and shake until it is evenly dispersed, and observe the morphology of the ropivacaine crystals after reconstitution with a microscope (Olympus, CX41).

[0244] Table 2-1 Compositions containing common dispersants

[0245]

[0246] Table 2-2 Redissolution dispersibility and crystal morphology

[0247] Composition No. Redispersibility Crystal morphology 6006 Easy to disperse Irregular crystals 6007 Easy to disperse Irregular crystals 6008 Easy to disperse Irregular crystals 6009 Easy to disperse Irregular crystals

[0248] The results showed that the addition of common dispersants could improve the resolubility of the composition. However, microscopic observation showed that the morphology of ropivacaine crystals in the resolubilized suspension was irregular. The morphology of ropivacaine crystals in the resolubilized composition 6006 was as follows: Figure 1As shown, the morphology of ropivacaine after reconstitution of other dispersant compositions was observed by microscopy. Figure 1 Similarly, there is a phenomenon of crystal aggregation, and the crystal sizes vary greatly.

[0249] (2) Compositions containing phospholipid dispersants

[0250] Weigh the prescribed amount of ropivacaine and phospholipid dispersant according to Table 2-3 into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense 1.5mL / bottle, and freeze-dry according to Table 1-3. Add 1.5mL of normal saline to the lyophilized powder and shake until it is evenly dispersed, and observe the morphology of the reconstituted ropivacaine crystals under a microscope (Olympus, CX41).

[0251] Table 2-3 Compositions containing phospholipid dispersants

[0252]

[0253] *6012 and 6017 showed precipitation in the solution before freeze-drying and were not further studied.

[0254] Table 2-4 Redissolution dispersibility and crystal morphology

[0255] serial number Redispersibility Crystal morphology 6010 Easy to disperse Irregular crystals 6011 Easy to disperse Irregular crystals 6013 Easy to disperse Irregular crystals 6014 Easy to disperse Irregular crystals 6015 Easy to disperse Irregular crystals 6016 Easy to disperse Irregular crystals

[0256] The results showed that the addition of phospholipid dispersants, except for HSPC and DSPC, could improve the resolubility of the composition. However, the morphology of ropivacaine crystals after resolubilization was irregular, which was different from the Figure 1 Similarly, there is a phenomenon of crystal aggregation, and the crystal sizes vary greatly.

[0257] (3) Study on the effect of dispersant dosage on crystal morphology

[0258] Taking polysorbate 20 and DMPC as representatives, the effects of different molar ratios of ropivacaine and dispersant on crystal morphology were investigated. The prescribed amount of ropivacaine and dispersant were weighed into a Schott bottle according to Tables 2-5 and 2-6, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the solution was filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. Freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed, and the morphology of the reconstituted ropivacaine crystals was observed using a microscope (Olympus, CX41).

[0259] Table 2-5 Compositions with different DMPC dosages

[0260]

[0261] Table 2-6 Compositions with different amounts of polysorbate 20

[0262]

[0263]

[0264] The results showed that the resolubility of the composition could be improved when the molar ratio of ropivacaine to dispersant was within the range of 50:1 to 1:1, but the morphology of ropivacaine crystals was irregular under microscopic observation. Figure 1 Similarly, there is a phenomenon of crystal aggregation, and the crystal size varies greatly. The amount of dispersant used only affects the speed of dispersion, and does not affect the crystal morphology.

[0265] As shown in Example 2, after adding the dispersant, the crystal form of ropivacaine in the suspension is irregular, the crystal size or size is not uniform, and there is easily a crystal aggregation phenomenon. And these will lead to the unstable quality and uncontrollable quality of the suspension product when it is used as an injection, and it is also easy to cause the adverse consequences of blocking the needle when the injection is used later. Therefore, the present invention intends to improve the crystal form and crystal size of ropivacaine in the suspension by screening and adding a suitable additive and the ratio between each component, and then control the product quality of the suspension.

[0266] Example 3

[0267] Crystal morphology improvement research

[0268] (1) Study on solvent ratio

[0269] Using DMPC as a dispersant, the effect of different tert-butyl alcohol / water ratios on crystal morphology was investigated. According to Table 3-1, the prescribed amount of ropivacaine and DMPC were weighed into a Schott bottle, and the tert-butyl alcohol aqueous solution was added. The mixture was heated and stirred appropriately until completely dissolved. After filtering through a 0.22 μm filter membrane, the mixture was divided into 2 mL / bottle and freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed, and the morphology of the reconstituted ropivacaine crystals was observed using a microscope (Olympus, CX41).

[0270] Table 3-1 Prescription composition

[0271]

[0272] Table 3-2 Crystal morphology

[0273] Composition No. Crystal morphology 6030 Irregular crystals 6031 Irregular crystals 6032 Irregular crystals 6033 Irregular crystals 6034 Irregular crystals 6035 Irregular crystals

[0274] The results showed that when the proportion of tert-butyl alcohol was changed on the basis of only containing dispersant, ropivacaine was irregular crystals, and there was no significant improvement in the morphology. The ropivacaine crystal morphology of the composition 6030-6035 was Figure 2 .

[0275] (2) Addition of alcohol or sugar additives

[0276] Different alcohol additives were added to DMPC and TW20 as dispersants, and it was unexpectedly found that high-carbon alcohol additives had an effect on the crystal morphology of ropivacaine. According to Tables 3-3 and 3-4, the prescribed amount of ropivacaine, dispersant and additives were weighed into a Schott bottle, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the solution was filtered through a 0.22μm filter membrane and dispensed into 2mL / bottle. Freeze-dried according to Table 1-3. 2mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed, and the morphology of the reconstituted ropivacaine crystals was observed under a microscope (Olympus, CX41).

[0277] Table 3-3 Compositions containing water-soluble alcohol or sugar additives

[0278]

[0279] * Compositions 6038 and 6043 containing lactose were not soluble and were not studied further.

[0280] Table 3-4 Compositions containing water-insoluble alcohol additives

[0281]

[0282] Table 3-5 Crystal morphology results

[0283] Composition No. Crystal morphology Composition No. Crystal morphology 6036 Irregular crystals 6046 Regular crystals (rod-shaped) 6037 Irregular crystals 6047 Irregular crystals 6039 Irregular crystals 6048 Irregular crystals 6040 Irregular crystals 6049 Regular crystals (rod-shaped) 6041 Irregular crystals 6050 Regular crystals (rod-shaped) 6042 Irregular crystals 6051 Irregular crystals 6044 Irregular crystals 6052 Irregular crystals 6045 Irregular crystals 6053 Regular crystals (rods or blocks)

[0284] The results showed that according to the screening results of alcohol additives, ropivacaine was irregular crystals after reconstitution of the combination of water-soluble alcohol or sugar additives. Figure 3 ; It was unexpectedly found that only cholesterol and octadecyl alcohol could improve the crystal morphology, making the crystals regular rod-shaped or block-shaped, while other alcohol additives were irregular crystals (similar to Figure 3 similar), Figure 4 The crystalline morphology of ropivacaine of compositions 6046 and 6049 is shown in FIG.

[0285] Taking cholesterol as an example, the crystal morphology of ropivacaine in different dispersants was investigated. The prescribed amount of ropivacaine, dispersant and additives were weighed into a Schott bottle according to Tables 3-6 and 3-7, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the mixture was divided into 2 mL / bottle after filtering through a 0.22 μm filter membrane and freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed. The crystal morphology of ropivacaine after reconstitution was observed under a microscope (Olympus, CX41), and all were consistent with the above results. Figure 4 Similarly, D50 and D90 were measured using a laser particle size analyzer (OMEC, Topsizer).

[0286] 3-6 Compositions containing common dispersants

[0287]

[0288] Table 3-7 Compositions containing phospholipid dispersants

[0289]

[0290] (3) Research on cholesterol analogs

[0291] Select substances with similar structures to cholesterol for investigation. According to Tables 3-8 and 3-9, weigh the prescribed amount of ropivacaine, dispersant and additives into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense 2mL / bottle. Freeze-dry according to Table 1-3. Add 2mL of normal saline to the freeze-dried powder and shake until it is evenly dispersed, and observe the morphology of the ropivacaine crystals after reconstitution with a microscope (Olympus, CX41).

[0292] Table 3-8 Composition information

[0293]

[0294]

[0295] Table 3-9 Composition information

[0296]

[0297] Table 3-10 Crystal morphology results

[0298] Composition No. Crystal morphology Composition No. Crystal morphology 6174 Regular crystals (rod-shaped) 6178 Regular crystals (rod-shaped) 6175 Regular crystals (rod-shaped) 6179 Regular crystals (rod-shaped) 6176 Regular crystals (rod-shaped) 6180 Regular crystals (rod-shaped) 6177 Regular crystals (rod-shaped) 6181 Regular crystals (rod-shaped)

[0299] The results show that: the present invention unexpectedly discovered that bile acid and its derivatives or salts can improve the crystal morphology, making the crystals regular rod-shaped or block-shaped.

[0300] (4) Addition of metal ion additives

[0301] Metal ion additives were added to the dispersant to investigate the effect of metal ion additives on the crystal morphology of ropivacaine. According to Tables 3-11 and 3-12, the prescribed amount of ropivacaine, dispersant and additives were weighed into a Schott bottle, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the solution was filtered through a 0.22 μm filter membrane and divided into 1.5 mL or 2 mL / bottle. The solution was freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed, and the crystal morphology of ropivacaine after reconstitution was observed under a microscope (Olympus, CX41).

[0302] Table 3-11 Compositions containing metal ions

[0303]

[0304] Table 3-12 Compositions containing metal ions

[0305]

[0306]

[0307] The results show that the present invention unexpectedly found that adding metal ions to the system can reduce large-size crystals, while improving the uniformity of product crystal distribution and appropriately improving the crystal morphology. The crystal morphology of ropivacaine after reconstitution without metal ions (composition 6010) and with metal ions (composition 6064) is shown in Figure 2. Figure 5 .

[0308] Example 4

[0309] Cholesterol research

[0310] Using DMPC as a dispersant, the effects of different molar ratios of active ingredients to cholesterol on dispersibility and crystal morphology were investigated. According to Table 4-1, the prescribed amount of ropivacaine, DMPC and cholesterol were weighed into a Schott bottle, and tert-butyl alcohol aqueous solution was added. The mixture was heated and stirred appropriately until completely dissolved. After filtering through a 0.22 μm filter membrane, the mixture was divided into 2 mL / bottle and freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed. The crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer). At the same time, a composition without cholesterol was used as a comparison, and the precipitation time of the ropivacaine crystals was observed at rest, as shown in Table 4-2.

[0311] Table 4-1 Compositions with different cholesterol dosages

[0312]

[0313] Table 4-2 Dispersibility and crystal morphology

[0314]

[0315] The results showed that the cholesterol-free samples were irregular crystals. Figure 6 When the molar ratio of ropivacaine: cholesterol is greater than 7:1, a small amount of rod-shaped crystals can be seen, but there are still a large number of irregular crystals. Figure 6 Composition 6076 in; when the molar ratio of ropivacaine: cholesterol is ≤7:1, rod-shaped crystals are basically formed, see Figure 6 The composition 6078. In addition, the addition of cholesterol can prolong the sedimentation time of ropivacaine crystals and increase the physical stability of the reconstituted drug solution.

[0316] Example 5

[0317] Research on Metal Ion Salts

[0318] (1) Research on types of metal ion salts

[0319] Using DMPC as a dispersant, the effects of monovalent metal ions and divalent metal ion salts on crystal morphology were investigated. According to Tables 5-1 and 5-2, the prescribed amount of ropivacaine, DMPC and different metal ion salts were weighed into a Schott bottle, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the solution was filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. Freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed. The crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0320] Table 5-1 Compositions containing monovalent metal ion salts

[0321]

[0322] Table 5-2 Compositions containing divalent metal ion salts

[0323]

[0324] The results showed that both monovalent metal ion and divalent metal ion salts can reduce the size of large crystals and appropriately improve the crystal morphology, making the crystals shorter and thicker. The divalent metal ion salts have a more significant effect. The crystal morphology of ropivacaine in composition 6083 and composition 6087 is shown in Figure 2. Figure 7 .

[0325] (2) Study on metal ion dosage

[0326] The effects of the ratio of active ingredients to metal ions on the crystal morphology were investigated separately. Sodium ions were selected for monovalent metal ions and magnesium ions for divalent metal ions. Considering the injection route, sodium chloride and magnesium chloride were selected for research. According to Tables 5-3 and 5-4, the prescribed amount of ropivacaine, DMPC and different metal ion salts were weighed into a Schott bottle, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the mixture was filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. Freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed. The crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0327] Table 5-3 Compositions containing monovalent metal ion salts

[0328]

[0329]

[0330] Table 5-4 Compositions containing divalent metal ion salts

[0331]

[0332] The results show that adding a certain amount of metal ions can reduce the size of large crystals and appropriately improve the crystal morphology. Figure 8 .

[0333] (3) Research on methods of introducing metal ions

[0334] To further investigate the influence of metal ions, the freeze-dried powder was reconstituted with a solution containing a metal ion salt after freeze-drying to investigate the influence of the metal ion addition method on the crystal morphology. Sodium chloride aqueous solution and magnesium chloride aqueous solution were prepared separately, and added to the composition 6105 (Table 5-5) at a molar ratio of ropivacaine:metal ion of 1:1.37. After shaking until uniform dispersion, the crystal morphology of ropivacaine after reconstitution was observed with a microscope (Olympus, CX41). Fig. 9 .

[0335] Table 5-5 Composition information

[0336]

[0337] Table 5-6 Crystal morphology after re-dissolution

[0338] Reconstitution medium Crystal morphology Purified water Irregular crystals Sodium chloride aqueous solution Irregular crystals Magnesium chloride aqueous solution Irregular crystals

[0339] The results showed that metal ions must be added to the initial formulation in order to reduce the size of large crystals and appropriately improve the crystal morphology.

[0340] Example 6

[0341] Composition containing cholesterol and metal ions

[0342] Cholesterol and metal ions were added to the composition at the same time to investigate the effect on the crystal morphology. Sodium chloride and magnesium chloride were selected as metal ion salts for the study, and were added at a molar ratio of ropivacaine: cholesterol: metal ion of 1:0.18:1.37. The prescription amount of ropivacaine, DMPC, cholesterol and metal ions were weighed according to Table 6-1 into a Schott bottle, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the mixture was divided into 2 mL / bottle after passing through a 0.22 μm filter membrane, and freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed, and the crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0343] Table 6-1 Composition information

[0344]

[0345] The results showed that the addition of cholesterol and metal ions had a synergistic effect, which could make ropivacaine form more regular rod-shaped crystals. The ropivacaine crystal morphology of compositions 6106 and 6107 was Fig.10 After the crystals of composite 6106 were separated, they were photographed under a scanning electron microscope (FEI, Quanta FEG 250, USA), and three-dimensional regular rod-shaped crystals were observed. Fig.11 .

[0346] The molar ratio of ropivacaine and cholesterol was fixed, and the effect of different metal ion dosages on the crystal morphology was investigated. The prescribed amount of ropivacaine, DMPC, cholesterol and metal ions were weighed into a Schott bottle according to Table 6-2 and Table 6-3, and tert-butyl alcohol aqueous solution was added. After appropriate heating and stirring until completely dissolved, the solution was filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. Freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed. The crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0347] Table 6-2 Composition information

[0348]

[0349] Table 6-3 Composition information

[0350]

[0351]

[0352] The results showed that when the molar ratio of ropivacaine to cholesterol was fixed and a certain amount of metal ions were added, the ropivacaine crystals and Fig.10Consistent.

[0353] The molar ratio of ropivacaine and metal ions was fixed, and the effect of different cholesterol dosages on crystal morphology was investigated. The prescribed amount of ropivacaine, DMPC, cholesterol and metal ions were weighed into a Schott bottle according to Table 6-4, and TBA aqueous solution was added. After appropriate heating and stirring until completely dissolved, the mixture was filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. Freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until evenly dispersed. The crystal morphology of the reconstituted ropivacaine was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0354] Table 6-4 Composition information

[0355]

[0356] The results showed that when the molar ratio of ropivacaine to metal ions was fixed and the molar ratio of ropivacaine to cholesterol was ≤7:1, ropivacaine crystals and Fig.10 Consistent.

[0357] Example 7

[0358] Compositions of different dispersant types and amounts

[0359] (1) Compositions of different dispersant types

[0360] Cholesterol and metal ions were added to the composition at the same time, and the type of dispersant was changed to investigate the effect on the crystal morphology. Sodium chloride was selected as the metal ion salt for the study. The prescribed amount of ropivacaine, dispersant, cholesterol and metal ions were weighed into a Schott bottle according to Table 7-1, and tert-butyl alcohol / water solution was added. The solution was heated and stirred appropriately until completely dissolved, and then filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle, and freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed, and the crystal morphology of ropivacaine after reconstitution was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0361] Table 7-1 Compositions of different dispersant types

[0362]

[0363]

[0364] The results showed that the ropivacaine crystals after reconstitution of the above composition were all in the form of rod-shaped crystals. Fig.12 , indicating that the type of dispersant does not affect the crystal morphology.

[0365] (2) Compositions with different dispersant dosages

[0366] Cholesterol and metal ions were added to the composition at the same time, and DMPC and polysorbate 20 were used as dispersants to investigate the effect of the amount of dispersant on the crystal morphology. Sodium chloride was selected as the metal ion salt for the study. The prescription amount of ropivacaine, dispersant, cholesterol and metal ions were weighed into a Schott bottle according to Tables 7-2 to 7-4, and tert-butyl alcohol / water solution was added. The solution was heated and stirred appropriately until completely dissolved, and then filtered through a 0.22um filter membrane and dispensed into 2mL / bottle, and freeze-dried according to Table 1-3. 2mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed, and the crystal morphology of ropivacaine after reconstitution was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0367] Table 7-2 Compositions with different dispersant dosages

[0368]

[0369] Table 7-3 Compositions with different dispersant dosages

[0370]

[0371] Table 7-4 Compositions with different dispersant dosages

[0372]

[0373] The results showed that the ropivacaine crystals after reconstitution of the above composition were all in the form of rod-shaped crystals. Fig.12 This indicates that the amount of dispersant within the above molar ratio range does not affect the crystal morphology.

[0374] Example 8

[0375] Study of different solvent ratios

[0376] Cholesterol and metal ions were added to the composition at the same time, and the ratio of tert-butyl alcohol / water was changed to investigate the effect on the crystal morphology. Sodium chloride was selected as the metal ion salt and DMPC was selected as the dispersant for the study. The prescription amount of ropivacaine, DMPC, cholesterol and sodium chloride were weighed into a Schott bottle according to Table 8-1, and the tert-butyl alcohol / water solution was added. The solution was heated and stirred appropriately until it was completely dissolved, and then filtered through a 0.22 μm filter membrane and dispensed into 2 mL / bottle. The solution was freeze-dried according to Table 1-3. 2 mL of normal saline was added to the freeze-dried powder and shaken until it was evenly dispersed. The crystal morphology of ropivacaine after reconstitution was observed with a microscope (Olympus, CX41), and the D50 and D90 were detected with a laser particle size analyzer (OMEC, Topsizer).

[0377] Table 8-1 Compositions of different solvent ratios

[0378]

[0379] The results showed that the compositions with different tert-butyl alcohol ratios were all regular rod-shaped crystals after re-dissolution, among which the ropivacaine crystal morphology of composition 6129 was Fig.13 .

[0380] Example 9

[0381] Ropivacaine can be prepared directly by alkalizing a pharmaceutically acceptable salt of ropivacaine.

[0382] If the active ingredient is a salt, the crystal morphology can be improved by adding a base containing metal ions, such as sodium hydroxide, potassium hydroxide, sodium bicarbonate, etc. Weigh the prescribed amount of ropivacaine hydrochloride, DMPC, cholesterol and metal ions according to Table 9-1 into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of normal saline to the freeze-dried powder and shake until it is evenly dispersed, and observe the crystal morphology of ropivacaine after reconstitution with a microscope (Olympus, CX41), and use a laser particle size analyzer (OMEC, Topsizer) to detect D50 and D90.

[0383] Table 9-1 Composition information

[0384]

[0385]

[0386] The results showed that the morphology of ropivacaine crystals after reconstitution was rod-shaped. Fig.10 Consistent.

[0387] Example 10

[0388] Combinations of different active ingredients

[0389] According to Table 10-1, weigh the active ingredient, DMPC, cholesterol and sodium chloride in the prescription amount into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of normal saline to the lyophilized powder and shake until it is evenly dispersed, and observe the crystal morphology of the active ingredient after reconstitution with a microscope (Olympus, CX41), all of which are irregular crystals, and regular crystals cannot be formed.

[0390] Table 10-1 Composition information

[0391]

[0392] Embodiment 11

[0393] Compositions containing different lyophilization protectants

[0394] According to Table 11-1, weigh the prescribed amount of ropivacaine, DMPC, cholesterol, sodium chloride and lyophilization protective agent into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle. Freeze-dry according to Table 1-3. Add 2mL of normal saline to the lyophilized powder and shake until it is evenly dispersed. Use a microscope (Olympus, CX41) to observe the morphology of the ropivacaine crystals after reconstitution. They are all the same as Fig.10 The results were consistent with those of the samples. Meanwhile, the D90 was detected by a laser particle size analyzer (OMEC, Topsizer), which was all within the range of 10 to 50 μm.

[0395] Table 11-1 Compositions containing different lyophilization protective agents

[0396]

[0397] Example 12

[0398] In vivo administration of the composition

[0399] Pharmacokinetics in rats

[0400] SD rats weighing about 200 g were allowed to drink water and eat freely during the whole experiment. Each group was given medication by subcutaneous injection. The sample information is shown in Table 12-1.

[0401] According to Table 12-1, weigh the prescribed amount of ropivacaine, DMPC, cholesterol, and sodium chloride into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of normal saline to the lyophilized powder and shake until it is evenly dispersed to form a 20mg / mL suspension, and use a laser particle size analyzer (OMEC, Topsizer) to detect D50 and D90.

[0402] Each SD rat was given a dose of 20 mg / kg. About 0.3 mL of blood was collected from each group of animals at 0 hour before administration and at 15 minutes, 30 minutes, 1, 2, 4, 8, 10, 24, 32, 48, 56 and 72 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000 rpm for 5 minutes and then the plasma was collected. The drug concentration in the plasma sample was then detected by LC-MS / MS. The blood drug concentration curve is shown in Fig.14 .

[0403] Table 12-1 Composition of the composition

[0404]

[0405] The results show that the compositions of the present invention all have good sustained-release effects.

[0406] Embodiment 13

[0407] Pharmaceutical compositions at different pH

[0408] Acidic / alkaline regulators were added to the drug composition or different pH buffers were used for reconstitution, and the pH of the reconstituted drug solution was adjusted to investigate the effect of pH on free drug (drug dissolved in the solution), ropivacaine crystal particle size and sustained release.

[0409] (1) Pharmaceutical composition containing an acidity regulator

[0410] According to Table 13-1, weigh the prescribed amount of ropivacaine, DMPC, cholesterol, sodium chloride and maleic acid into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of normal saline to the lyophilized powder and shake until it is evenly dispersed, and examine the pH, particle size distribution and free drug differences of the composition after reconstitution.

[0411] Table 13-1 Pharmaceutical compositions containing different amounts of acidity regulators

[0412]

[0413] Table 13-2 pH, free drug and particle size distribution

[0414]

[0415]

[0416] The results showed that pH affected the concentration of free drug after reconstitution, but did not affect the particle size distribution. Composition 6133 and composition 6144 were subjected to in vitro release studies. The reconstituted drug solution was added to a dialysis bag, placed in 200 mL PBS7.4 buffer, shaken at 50 rpm in a shaker at 37°C, and samples were taken to detect the drug release. The results are shown in Table 13-3.

[0417] Table 13-3 In vitro release results

[0418]

[0419] The results showed that after adding the acidic regulator into the composition, the free drug concentration in the composition was changed, and the drug release was increased after 30 minutes.

[0420] (2) Pharmaceutical compositions containing alkaline regulators

[0421] According to Table 13-4, weigh the prescribed amount of ropivacaine hydrochloride, DMPC, cholesterol, sodium hydroxide and sodium chloride into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 2mL / bottle, and freeze-dry according to Table 1-3. Add 2mL of normal saline to the lyophilized powder and shake until it is evenly dispersed, and examine the differences in pH and free drug after the composition is reconstituted.

[0422] Table 13-4 Pharmaceutical compositions containing different amounts of alkaline regulators

[0423]

[0424] Table 13-5 pH and free drugs

[0425]

[0426] The results showed that the release could be regulated by adjusting the ratio of ropivacaine salt and alkaline regulator to control the free drug concentration.

[0427] (3) Compositions reconstituted using different pH buffers

[0428] The composition 6133 in Table 13-1 was reconstituted with buffer solutions of pH 5.0 to 7.4, and the pH and free drug of the composition were investigated.

[0429] Table 13-6 pH and free drug results

[0430]

[0431]

[0432] The results show that the free drug concentration is different when the composition is reconstituted with different pH buffers. The release can be adjusted by adjusting the pH of the buffer used for reconstitution to control the free drug concentration.

[0433] (4) In vivo administration of compositions of different pH values

[0434] Pharmacokinetics in rats

[0435] SD rats weighing about 200g were allowed to drink water and eat freely during the whole experiment. Each group was administered by subcutaneous injection, and the sample information is shown in Table 13-7. Each SD rat was administered at a dose of 20mg / kg, and about 0.3mL of blood samples were collected from each group of animals at 0 hour before administration and at 15min, 30min, 1, 2, 4, 8, 10, 24, 32, 48, 56 and 72 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000rpm for 5min to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 13-8.

[0436] Table 13-7 Composition formula composition

[0437]

[0438] Table 13-8 Differences in blood drug concentrations in the early period (0 to 2 hours)

[0439]

[0440] The results showed that changing the pH of the composition only changed the initial Cmax and did not affect the overall sustained-release effect.

[0441] Pharmacokinetics in dogs

[0442] Beagles weighing about 10 kg were allowed to drink water and eat freely throughout the experiment. Each group was administered subcutaneously, and the sample information is shown in Table 13-9. Each beagle was administered at a dose of 6 mg / kg, and about 0.3 mL of blood samples were collected from each group of animals at 0 hour before administration, and at 15 minutes, 30 minutes, 1, 2, 4, 8, 10, 24, 32, 48, 56, 72, 96, 120, 144 and 168 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000 rpm for 5 minutes to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 13-10.

[0443] Table 13-9 Composition formula composition

[0444]

[0445]

[0446] Table 13-10 Differences in blood drug concentrations in the early period (0 to 2 hours)

[0447]

[0448] The results showed that by adjusting the pH of the composition, the early drug release can be improved, the blood drug concentration can be increased from 0.25h to 2h, and the purpose of rapid onset of action can be achieved.

[0449] Embodiment 14

[0450] Comparative study with existing technologies

[0451] At present, the long-acting sustained-release aqueous systems of ropivacaine disclosed in patent literature are mainly ordinary suspension systems, liposome systems, microspheres, etc. Due to the various limitations of microspheres, the applicant selected ordinary suspension systems and liposome systems for comparative study.

[0452] (1) Comparative study with ordinary suspension system

[0453] The common suspension system commonly used in the published patent literature uses Tween or poloxamer as a dispersant and sodium carboxymethyl cellulose as a suspending agent. The crystal particle size is controlled by shearing. The preparation method is as follows:

[0454] Sodium carboxymethyl cellulose, sodium chloride and poloxamer 188 were weighed and dissolved in 45 ml of water for injection. After complete dissolution, ropivacaine was weighed and added to the above solution. High shear was applied at 8000 rpm for 10 minutes to fully disperse the ropivacaine. The solution was then diluted to 45 ml with water for injection and dispensed into 2 ml / bottle as Comparative Example 1.

[0455] The pharmacokinetic studies of the composition 6106 of the present invention and the composition of comparative example 1 were conducted in rats and dogs, respectively, and the results are as follows:

[0456] Pharmacokinetic study in rats

[0457] SD rats weighing about 200g were allowed to drink water and eat freely during the whole experiment. Each group was administered with subcutaneous injection. The sample information is shown in Table 14-1. Each SD rat was administered with a dose of 20mg / kg. About 0.3mL of blood samples were collected from each group of animals at 0 hour before administration and at 15min, 30min, 1, 2, 4, 8, 10, 24, 32, 48, 56 and 72 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000rpm for 5min to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 14-2.

[0458] Table 14-1 Composition Information

[0459]

[0460]

[0461] Table 14-2 Pharmacokinetic parameters

[0462]

[0463] Pharmacokinetic study in dogs

[0464] Beagles weighing about 10 kg were allowed to drink water and eat freely during the whole experiment. Each group was administered by subcutaneous injection. The sample information is shown in Table 14-3. Each beagle was administered at a dose of 6 mg / kg. About 0.3 mL of blood samples were collected from each group of animals at 0 hour before administration and at 15 minutes, 30 minutes, 1, 2, 4, 8, 10, 24, 32, 48, 56, 72, 96, 120, 144 and 168 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000 rpm for 5 minutes to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 14-4.

[0465] Table 14-3 Composition information

[0466]

[0467] Table 14-4 Pharmacokinetic parameters

[0468]

[0469] The results showed that compared with the common suspension system, the suspension injection of the present application has excellent pharmacokinetic properties in vivo, for example, T 1 / 2 In the process of scaled-up production, the suspension injection of the present application can be filtered and sterilized, and the sterility guarantee is high.

[0470] (2) Comparative study with liposome system

[0471] The liposome systems in the disclosed patents are mainly multilamellar liposomes and multivesicular liposomes, among which multilamellar liposomes are in the clinical research stage, and multivesicular liposomes already have a marketed preparation EXPAREL with bupivacaine as the active ingredient.

[0472] Multilamellar liposomes were prepared as Comparative Examples 2 and 3 as follows:

[0473] Weigh the prescribed amount of active ingredients, DMPC, and cholesterol into a Schott bottle, add tert-butyl alcohol aqueous solution, heat and stir appropriately until completely dissolved, filter through a 0.22μm filter membrane, and dispense into 5mL / bottle. Freeze at -45℃ for 120min, dry once at 0℃ for 720min, and dry twice at 30℃ for 1080min for freeze-drying. Add 5mL of normal saline to the freeze-dried powder and shake until it is evenly dispersed for comparative study.

[0474] The pharmacokinetic study and local safety comparison study were conducted in rats. Meanwhile, the pharmacokinetic study in dogs and the pharmacodynamic study in guinea pigs were conducted with EXPAREL as the control drug. The results are as follows:

[0475] Pharmacokinetic study in rats

[0476] SD rats weighing about 200g were allowed to drink water and eat freely during the whole experiment. Each group was administered by subcutaneous injection, and the sample information is shown in Table 14-5. Each SD rat was administered at a dose of 20mg / kg, and about 0.3mL of blood samples were collected from each group of animals at 0 hour before administration and at 15min, 30min, 1, 2, 4, 8, 10, 24, 32, 48, 56 and 72 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000rpm for 5min to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 14-6.

[0477] Table 14-5 Composition information

[0478]

[0479] Table 14-6 Pharmacokinetic parameters

[0480]

[0481] Pharmacokinetic study in dogs

[0482] Beagles weighing about 10 kg were allowed to drink water and eat freely throughout the experiment. The marketed preparation EXPAREL was used as the control group, and the composition 6144 and EXPAREL were administered by subcutaneous injection. The composition information is shown in Table 14-7. Each beagle was administered at a dose of 6 mg / kg. About 0.3 mL of blood samples were collected from each group of animals at 0 hour before administration and at 15 minutes, 30 minutes, 1, 2, 4, 8, 10, 24, 32, 48, 56, 72, 96, 120, 144 and 168 hours after administration into EDTA-2K+ anticoagulated blood collection tubes. The whole blood was centrifuged at 8000 rpm for 5 minutes to collect plasma, and then the drug concentration in the plasma sample was detected by LC-MS / MS. The pharmacokinetic parameters are shown in Table 14-8.

[0483] Table 14-7 Composition Information

[0484]

[0485] Table 14-8 Pharmacokinetic parameters

[0486]

[0487] In vivo pharmacodynamic study in rats

[0488] The marketed multivesicular liposome EXPAREL was used as the control group, and the composition 6144 and EXPAREL were administered by subcutaneous injection. The composition information is shown in Table 14-7. The EXPAREL group was administered at 6.65 mg / head, and the composition 6144 was administered at 10 mg / head (equivalent dose to EXPAREL).

[0489] The basal pain threshold was tested two days before surgery (Day-2 and Day-1) and on the day of surgery (Day 0). Then the preparation of the incision postoperative pain model was started. All rats were first induced with 3.5-4% isoflurane oxygen for anesthesia, and then maintained with 1.5-2% isoflurane. The foot skin was prepared with povidone-iodine solution and alcohol. Under sterile conditions, a 1-cm long longitudinal incision was made with a No. 11 scalpel blade 0.5 cm forward from the plantar of each rat to separate the fascia and muscle, raise the flexor muscle, and cut longitudinally along the muscle. After the wound was opened with a sterile cotton swab for 2 hours, two discontinuous sutures were made at the incision site with 3-0 silk thread, the skin was sutured, and then the skin at the incision site was smeared with povidone-iodine. After the operation was completed, the rats were returned to the breeding cage for recovery. The postoperative basal pain threshold before drug administration was measured 24 hours after surgery (set as Day 1), and then the drug was administered. The pain threshold at different times after drug administration was measured. The results are shown in the table. Fig.15 .

[0490] Topical safety study in rats

[0491] SD rats weighing about 200g were allowed to drink water and eat freely during the whole experiment. Each group was administered by subcutaneous injection. The sample information is shown in Table 14-9. Each SD rat was administered at a dose of 20mg / kg. The animals in each group were killed 72h after administration. The epidermis was cut open along the administration site to observe the subcutaneous state and local irritation of the preparation. The results are shown in Fig.16 .

[0492] Table 14-9 Composition information

[0493]

[0494] Table 14-11 Inflammation

[0495]

[0496] It can be seen from the above results that compared with the existing liposome system, the suspension injection of the present invention has excellent pharmacokinetic properties in vivo, for example, its T 1 / 2 The effect of local anesthesia (pain threshold) is better than that of the existing preparation EXPAREL; and the inflammatory response of the suspension injection is less or lighter, and the safety is also improved.

[0497] The embodiments of the present invention are described above in an exemplary manner. However, the protection scope of the present invention is not limited to the above exemplary embodiments. Any modifications, equivalent substitutions, improvements, etc. made by those skilled in the art within the spirit and principles of the present invention shall be included in the protection scope of the claims of this application.

Claims

1. A suspension of ropivacaine or a pharmaceutically acceptable salt thereof, comprising: a) ropivacaine or a pharmaceutically acceptable salt thereof; c) a pharmaceutically acceptable dispersant; The suspension further comprises the following b) and / or e): b) a pharmaceutically acceptable stabilizer; e) pharmaceutically acceptable inorganic salts; in, The ropivacaine or its pharmaceutically acceptable salt in the suspension exists in the form of rod-shaped crystals or block-shaped crystals; the D90 particle size of the ropivacaine or its pharmaceutically acceptable salt in the suspension is less than or equal to 200 μm; The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable dispersant is 50:1 to 1:1; The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salt, deoxycholic acid or its salt, taurodeoxycholic acid or its salt, ursodeoxycholic acid or its salt, chenodeoxycholic acid or its salt, glycocholic acid or its salt; The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable stabilizer is 0.5:1 to 7:1; The molar ratio of ropivacaine or its pharmaceutically acceptable salt to the pharmaceutically acceptable inorganic salt is ≥1:0.02; The pharmaceutically acceptable inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride; The pharmaceutically acceptable inorganic salt is added to the initial formulation containing ropivacaine or a pharmaceutically acceptable salt thereof.

2. The suspension according to claim 1, characterized in that The D90 particle size of ropivacaine or its pharmaceutically acceptable salt in the suspension is less than or equal to 150 μm.

3. The suspension according to claim 2, characterized in that The D90 particle size of ropivacaine or its pharmaceutically acceptable salt in the suspension is less than or equal to 120 μm.

4. The suspension according to claim 3, characterized in that The D90 particle size of ropivacaine or its pharmaceutically acceptable salt in the suspension is less than or equal to 100 μm.

5. The suspension according to any one of claims 1 to 4, characterized in that The pharmaceutically acceptable salt of ropivacaine is an acid salt of ropivacaine, that is, an addition salt of ropivacaine and a pharmaceutically acceptable acid.

6. The suspension according to claim 5, characterized in that The acid salt of ropivacaine includes, but is not limited to, one or more of the following salts of ropivacaine selected from the group consisting of acetate, benzoate, benzenesulfonate, hydrobromide, camphorsulfonate, hydrochloride, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hydroiodide, isethionate, lactate, lactobionate, dodecyl sulfate, malate, maleate, methanesulfonate, naphthoate, naphthoate, nitrate, stearate, palmitate, myristate, laurate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, and trifluoroacetate.

7. The suspension according to any one of claims 1 to 4, characterized in that The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, taurodeoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, sodium taurodeoxycholate, sodium ursodeoxycholate, sodium chenodeoxycholate, and sodium glycocholate.

8. The suspension according to any one of claims 1 to 4, characterized in that The pharmaceutically acceptable dispersant is selected from one or more of polysorbate, poloxamer, polyoxyethylene fatty acid ester, polyoxyethylene fatty acid ether, sucrose fatty acid ester, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate, and phospholipids.

9. The suspension according to claim 8, characterized in that The polysorbate is selected from one or more of polysorbate 80 (Tween 80) and polysorbate 20 (Tween 20); And / or, the phospholipid is selected from one or more of DMPC (dimyristoylphosphatidylcholine), DPPC (dipalmitoylphosphatidylcholine), DLPC (dilauroylphosphatidylcholine), SPC (soybean phosphatidylcholine), EPC (egg yolk lecithin), DEPC (dierucoylphosphatidylcholine), DOPC (dioleoylphosphatidylcholine), POPC (palmitoyloleoylphosphatidylcholine).

10. The suspension according to any one of claims 1 to 4, characterized in that The suspension may further comprise: d) clinically acceptable diluent.

11. The suspension according to claim 10, characterized in that Clinically acceptable diluents include but are not limited to one or more of water for injection, sodium chloride injection, glucose injection, lactated Ringer's solution, sucrose aqueous solution, xylitol aqueous solution, and pH buffer solution.

12. The suspension according to claim 11, characterized in that The suspension is a suspension injection; And / or, in the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is 0.1 mg / mL to 300 mg / mL.

13. The suspension according to claim 12, characterized in that In the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is 1 mg / mL to 50 mg / mL.

14. The suspension according to claim 13, characterized in that In the suspension, the concentration of ropivacaine or a pharmaceutically acceptable salt thereof is 2.5 mg / mL to 40 mg / mL.

15. The suspension according to any one of claims 1 to 4, characterized in that The molar ratio of the ropivacaine or its pharmaceutically acceptable salt to the pharmaceutically acceptable inorganic salt is 1:0.02 to 1:2.

0.

16. The suspension according to any one of claims 1 to 4, characterized in that The suspension may further comprise: f) a pharmaceutically acceptable pH adjusting agent.

17. The suspension according to claim 16, characterized in that The pH regulator is selected from alkaline pH regulators and acidic pH regulators; And / or, the pH value of the suspension is 6.0-9.

0.

18. The suspension according to claim 17, characterized in that The pH value of the suspension is 6.0-8.

5.

19. The suspension according to claim 18, characterized in that The pH value of the suspension is 6.0-8.

0.

20. The suspension according to claim 19, characterized in that The pH value of the suspension is 6.0-7.

5.

21. The suspension according to claim 17, characterized in that The ropivacaine in the suspension is prepared in situ by reacting a pharmaceutically acceptable salt of ropivacaine with a basic pH adjusting agent.

22. The suspension according to claim 21, characterized in that When ropivacaine is prepared in situ as claimed in claim 21, the molar ratio of the pharmaceutically acceptable salt of ropivacaine to the alkaline pH regulator is 1:0.5 to 1:2.

0.

23. The suspension according to any one of claims 1 to 4, characterized in that The suspension may further comprise: h) a pharmaceutically acceptable lyoprotectant.

24. The suspension according to claim 23, characterized in that The pharmaceutically acceptable lyoprotectant is selected from one or more of mannitol, lactose, trehalose, sucrose, maltose, dextrin, stachyose, gelatin, pectin, sugar alcohol, sorbitol, proline, histidine, lysine, arginine, polyethylene glycol or polyvinyl pyrrolidine.

25. A solid composition of ropivacaine or a pharmaceutically acceptable salt thereof, characterized in that: The solid composition comprises: i) ropivacaine or a pharmaceutically acceptable salt thereof; iii) a pharmaceutically acceptable dispersant; The solid composition further comprises the following ii) and / or v): ii) a pharmaceutically acceptable stabilizer; v) pharmaceutically acceptable inorganic salts; Wherein, the ropivacaine or its pharmaceutically acceptable salt in the solid composition exists in the form of rod-shaped crystals or block-shaped crystals; the D90 particle size of the ropivacaine or its pharmaceutically acceptable salt in the suspension is less than or equal to 200 μm; The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable dispersant is 50:1 to 1:1; The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salt, deoxycholic acid or its salt, taurodeoxycholic acid or its salt, ursodeoxycholic acid or its salt, chenodeoxycholic acid or its salt, glycocholic acid or its salt; The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable stabilizer is 0.5:1 to 7:1; The molar ratio of ropivacaine or its pharmaceutically acceptable salt to the pharmaceutically acceptable inorganic salt is ≥1:0.02; The pharmaceutically acceptable inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride.

26. The solid composition according to claim 25, characterized in that In the solid composition, the D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof is less than or equal to 150 μm.

27. The solid composition according to claim 26, wherein The D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof is less than or equal to 120 μm.

28. The solid composition according to claim 27, characterized in that The D90 particle size of ropivacaine or a pharmaceutically acceptable salt thereof is less than or equal to 100 μm.

29. The solid composition according to any one of claims 25 to 28, characterized in that The pharmaceutically acceptable salt of ropivacaine is an acid salt of ropivacaine, that is, an addition salt of ropivacaine and a pharmaceutically acceptable acid.

30. The solid composition according to claim 29, wherein The acid salt of ropivacaine includes, but is not limited to, one or more of the following salts of ropivacaine selected from the group consisting of acetate, benzoate, benzenesulfonate, hydrobromide, camphorsulfonate, hydrochloride, citrate, edisylate, fumarate, glucoheptonate, gluconate, glucuronate, hydroiodide, isethionate, lactate, lactobionate, dodecyl sulfate, malate, maleate, methanesulfonate, naphthoate, naphthoate, nitrate, stearate, palmitate, myristate, laurate, oleate, oxalate, pamoate, phosphate, polygalacturonate, succinate, sulfate, sulfosalicylate, tartrate, toluenesulfonate, and trifluoroacetate.

31. A solid composition according to any one of claims 25 to 28, characterized in that The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.

32. A solid composition according to any one of claims 25 to 28, characterized in that The pharmaceutically acceptable dispersant is selected from one or more of polysorbate (Tween), poloxamer, polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers, sucrose fatty acid esters, sodium lauryl sulfate, polyethylene glycol-15 hydroxystearate (HS-15), and phospholipids.

33. The solid composition of claim 32, wherein The polysorbate is selected from one or more of polysorbate 80 (Tween 80) and polysorbate 20 (Tween 20); And / or, the phospholipid is selected from one or more of DMPC (dimyristoylphosphatidylcholine), DPPC (dipalmitoylphosphatidylcholine), DLPC (dilauroylphosphatidylcholine), SPC (soybean phosphatidylcholine), EPC (egg yolk lecithin), DEPC (dierucoylphosphatidylcholine), DOPC (dioleoylphosphatidylcholine), POPC (palmitoyloleoylphosphatidylcholine).

34. A solid composition according to any one of claims 25 to 28, characterized in that The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to a pharmaceutically acceptable inorganic salt is 1:0.02 to 1:2.

0.

35. A solid composition according to any one of claims 25 to 28, characterized in that The solid composition may further comprise: v) a pharmaceutically acceptable pH adjusting agent.

36. The solid composition of claim 35, wherein The pH adjuster is selected from alkaline pH adjusters and acidic pH adjusters.

37. A solid composition according to any one of claims 25 to 28, characterized in that The solid composition is reconstituted to form a suspension.

38. The solid composition of claim 37, wherein The pH value of the suspension is 6.0-9.

0.

39. A solid composition according to any one of claims 25 to 28, characterized in that The solid composition may further comprise: vii) a pharmaceutically acceptable lyoprotectant.

40. The solid composition of claim 39, wherein The pharmaceutically acceptable lyoprotectant is selected from one or more of mannitol, lactose, trehalose, sucrose, maltose, dextrin, stachyose, gelatin, pectin, sugar alcohol, sorbitol, proline, histidine, lysine, arginine, polyethylene glycol or polyvinyl pyrrolidine.

41. A method for preparing a solid pharmaceutical composition, the method comprising: Drying the solution containing the active pharmaceutical ingredient to obtain the solid pharmaceutical composition; In the solid pharmaceutical composition obtained after drying, the pharmaceutical active ingredient exists in the form of rod-shaped crystals or block-shaped crystals; The solid pharmaceutical composition is a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof according to any one of claims 25 to 40.

42. The preparation method according to claim 41, characterized in that The preparation method comprises: sterilizing and filtering a solution containing active pharmaceutical ingredients, and drying the solution to obtain a solid pharmaceutical composition.

43. The preparation method according to any one of claims 41 to 42, characterized in that: The drying method includes evaporative drying, freeze drying and spray drying.

44. The preparation method according to claim 43, characterized in that The freeze-drying process includes a pre-freezing process and a drying process.

45. The preparation method according to claim 44, characterized in that The pre-freezing procedure includes a cooling step 1, an annealing step and a cooling step 2; And / or, the drying procedure includes a primary drying step and a secondary drying step.

46. ​​The preparation method according to any one of claims 41 to 42, characterized in that: The pharmaceutically active ingredient is dissolved in a solvent to form the solution containing the pharmaceutically active ingredient.

47. The preparation method according to claim 46, characterized in that The solvent is selected from inorganic solvents, organic solvents or mixtures thereof suitable for dissolving the pharmaceutically active ingredient.

48. The preparation method according to claim 47, characterized in that The solvent is water, an organic solvent or a co-solvent system comprising water and an organic solvent.

49. The preparation method according to claim 48, characterized in that In the co-solvent system of water and organic solvent, the volume percentage of the organic solvent is 1% to 99%.

50. The preparation method according to claim 49, characterized in that In the co-solvent system of water and organic solvent, the volume percentage of the organic solvent is 50% to 95%.

51. The preparation method according to claim 50, characterized in that The volume percentage of the organic solvent is 60% to 90%.

52. The preparation method according to claim 51, characterized in that The volume percentage of the organic solvent is 65%-85%.

53. The preparation method according to claim 41, characterized in that When the pharmaceutically active ingredient in the solution is a pharmaceutically acceptable salt, it can react with a pH adjuster in the solution to prepare the corresponding free active ingredient in situ.

54. A method for preparing a suspension, comprising redissolving the solid composition according to any one of claims 25 to 40 or the solid pharmaceutical composition prepared by the method according to any one of claims 41 to 53, thereby obtaining the suspension.

55. The preparation method according to claim 54, characterized in that The preparation method comprises mixing the solid composition according to any one of claims 25 to 40 or the solid pharmaceutical composition prepared by the preparation method according to any one of claims 41 to 53 with a clinically acceptable diluent to obtain a suspension.

56. The preparation method according to claim 55, characterized in that The clinically acceptable diluents include but are not limited to one or more of water for injection, sodium chloride injection, glucose injection, lactated Ringer's solution, sucrose solution, xylitol solution, and pH buffer solution.

57. Use of a pharmaceutically acceptable inorganic salt and / or a pharmaceutically acceptable stabilizer as a crystal stabilizer of ropivacaine or a pharmaceutically acceptable salt thereof in a method for preparing a suspension of ropivacaine or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 24, or a solid composition of ropivacaine or a pharmaceutically acceptable salt thereof according to any one of claims 25 to 40; The pharmaceutically acceptable inorganic salt and / or pharmaceutically acceptable stabilizer is used to promote the presence of ropivacaine or its pharmaceutically acceptable salt in the suspension or solid composition in the form of rod-shaped crystals or block-shaped crystals; The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid or its salt, deoxycholic acid or its salt, taurodeoxycholic acid or its salt, ursodeoxycholic acid or its salt, chenodeoxycholic acid or its salt, glycocholic acid or its salt; The molar ratio of ropivacaine or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable stabilizer is 0.5:1 to 7:1; The molar ratio of ropivacaine or its pharmaceutically acceptable salt to the pharmaceutically acceptable inorganic salt is ≥1:0.02; The pharmaceutically acceptable inorganic salt is added to an initial prescription comprising ropivacaine or a pharmaceutically acceptable salt thereof; The pharmaceutically acceptable inorganic salt is selected from one or more of sodium chloride, sodium sulfate, potassium chloride, potassium sulfate, potassium phosphate, ammonium sulfate, ammonium chloride, magnesium chloride, magnesium sulfate, calcium chloride, and barium chloride.

58. The use according to claim 57, characterized in that The pharmaceutically acceptable stabilizer is selected from one or more of cholesterol, octadecyl alcohol, cholic acid, deoxycholic acid, ursodeoxycholic acid, chenodeoxycholic acid, glycocholic acid, sodium cholate, sodium deoxycholate, and sodium taurodeoxycholate.

59. Use of the suspension according to any one of claims 1 to 24 or the solid composition according to any one of claims 25 to 40 in the preparation of a medicament for producing anesthesia, or for treating and / or preventing pain.

60. The use according to claim 59, characterized in that The suspension or solid composition is applied around nerves or to surgical wounds.

61. The use according to claim 60, characterized in that Administration is parenteral and / or topical.

62. The use according to claim 61, characterized in that Parenteral administration is selected from intravenous, intramuscular, subcutaneous, intra-articular, epidural, subarachnoid, incisional instillation, infiltration and nerve block.

63. The use according to claim 61, characterized in that Parenteral administration is selected from intramuscular, subcutaneous, intra-articular, epidural, subarachnoid, incisional instillation, infiltration and nerve block.

64. The use according to claim 59, characterized in that The pain is chronic postoperative pain or labor pain.

Citation Information

Cited By

  • Composition of ropivacaine or pharmaceutically acceptable salt of ropivacaine, and use of composition

    EP4751715A1

  • Composition of ropivacaine or pharmaceutically acceptable salt of ropivacaine, and use of composition

    WO2025021176A1